CVS Group

H1 2024 trading statement

  • Sectors : Pharma and healthcare
  • Companies : CVS Group

Ratings and price correct at time of issue.

  • CVS Group

    Closing Price: 1647p

  • RATING 09/03/21

  • PREVIOUS RATING N/A

Person's Name

Colin Grant

Analyst

DAVY VIEW

CVS has reported strong revenue growth of 11.4% year-on-year (yoy) and an EBITDA margin of 19.0% in its trading statement for H1 2024 to December 31st. These figures are in line with our forecasts. Capex is also in line and the company continues to make good progress acquiring business in Australia and the UK.

View full article

Download full report with analyst certification and important disclosures

Jan 25 2024, 07:10 GMT

Download